{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022710","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2026-05-13T20:05:25+00:00","discovered_at":"2026-05-13T20:07:00.323726+00:00","generated_at":"2026-05-13T22:10:29.831361+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dermata Therapeutics Q1 2026: cash $6.9M; R&D spend down to $0.4M; DTC skincare launch planned mid-2026","bullets":["Cash and cash equivalents $6.9M as of Mar 31, 2026, down from $7.5M at Dec 31, 2025; net ATM proceeds of $2.0M.","R&D expenses fell to $0.4M from $1.3M YoY, reflecting reduced clinical spending; SG&A rose to $1.5M from $1.1M.","Announced Tome skincare brand for DTC; first product (Foundational Treatment) expected to launch mid-2026.","Hired Kyra Peckaitis as VP of Marketing to lead Tome brand; cash expected to fund operations into Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022710","json":"https://secwatch.observer/filing/0001493152-26-022710.json","markdown":"https://secwatch.observer/filing/0001493152-26-022710.md","text":"https://secwatch.observer/filing/0001493152-26-022710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/0001493152-26-022710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:10:29.831361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}